The decreased LGR5, β-catenin, mTOR, and IL-6 levels, and increased miR-142-3p level in tumor samples collected from mice that received MSI-N1014, support our proposed anti-CRC mechanism of action. The gene discussed is IL6; the disease is neoplasm.